Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024

Rhea-AI Summary

Insmed Incorporated (Nasdaq:INSM) announced the release of its fourth-quarter and full year 2023 financial results on February 22, 2024. The company will host a conference call for investors to discuss the financial results and provide a business update. Shareholders and interested parties can participate in the conference call by dialing (888) 210-2654 or by accessing the webcast on the company's website. A replay of the call will be available for 90 days.

BRIDGEWATER, N.J., Feb. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth-quarter and full year 2023 financial results on Thursday, February 22, 2024.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, February 22, 2024, to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S. and international) and referencing access code 7862189. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately 1 hour after its completion through March 23, 2024, by dialing (800) 770-2030 (U.S. and international) and referencing access code 7862189. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan. Visit www.insmed.com to learn more.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-fourth-quarter-and-full-year-2023-financial-results-conference-call-on-thursday-february-22-2024-302057028.html

SOURCE Insmed Incorporated

FAQ

When will Insmed release its fourth-quarter and full year 2023 financial results?

Insmed will release its fourth-quarter and full year 2023 financial results on Thursday, February 22, 2024.

What time will the conference call for investors begin?

The conference call for investors will begin at 8:30 a.m. ET on Thursday, February 22, 2024.

How can shareholders and interested parties participate in the conference call?

Shareholders and interested parties can participate in the conference call by dialing (888) 210-2654 (U.S. and international) and referencing access code 7862189. The call will also be webcast live on the company's website at www.insmed.com.

How long will the replay of the conference call be accessible?

A replay of the conference call will be accessible approximately 1 hour after its completion through March 23, 2024.